4-{[benzyl(ethyl)amino]methyl}benzaldehyde | 1224099-41-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-{[benzyl(ethyl)amino]methyl}benzaldehyde
• 英文别名: 4-[[Benzyl(ethyl)amino]methyl]benzaldehyde
• CAS: 1224099-41-5
• 化学式: C₁₇H₁₉NO
• 分子量: 253.344
• InChiKey: LXXREVQKKWITAP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-甲氧基-1-茚酮 、 4-{[benzyl(ethyl)amino]methyl}benzaldehyde 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 2-{4-[(benzylethylamino)methyl]benzylidene}-6-methoxyindan-1-one
  参考文献：
  名称：

  Targeting Alzheimer’s disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238

  摘要：

  We report on a series of hybrid compounds structurally derived from donepezil and AP2238. This study was aimed at improving the activities of the reference compounds, donepezil and AP2238, and at broadening the range of activities of new derivatives as, due to the multifactorial nature of AD, molecules that modulate the activity of a single protein target are unable to significantly modify the progression of the disease. In particular, the indanone core from donepezil was linked to the phenyl-N-methylbenzylamino moiety from AP2238, through a double bond that was kept to evaluate the role of a lower flexibility in the biological activities. Moreover, SAR studies were performed to evaluate the role of different substituents in position 5 or 6 of the indanone ring in the interaction with the PAS, introducing also alkyl chains of different lengths carrying different amines at one end. Derivatives 21 and 22 proved to be the most active within the series and their potencies against AChE were in the same order of magnitude of the reference compounds. Compounds 15, 21-22, with a 5-carbon alkyl chain bearing an amino moiety at one end, better contacting the PAS, remarkably improved the inhibition of AChE-induced A beta aggregation with respect to the reference compounds. They also showed activity against self-aggregation of A beta(42) peptide, the most amyloidogenic form of amyloid produced in AD brains, while the reference compounds resulted completely ineffective. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.01.071
• 作为产物：
  描述：

  4-溴甲基苯甲酸甲酯 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 12.0h， 生成 4-{[benzyl(ethyl)amino]methyl}benzaldehyde
  参考文献：
  名称：

  具有 AChE 和 MAO-B 双重抑制活性的新型 E/Z 2-Benzylideneindan-1-One 光开关的研究

  摘要：

  与更传统的“一种疾病一目标一药物”相反，多靶点治疗策略可能有望治疗多因素神经退行性综合征，例如阿尔茨海默病（AD）和相关痴呆症。最近，我们将光药理学方法与多靶点定向配体（MTDL）设计策略相结合，公开了一种新型多奈哌齐类化合物，即2-(4-((二乙氨基)甲基)亚苄基)-5-甲氧基-2,3-二氢-1H-茚-1-酮 (1a)，其 E 异构体形式（UV-B 光诱导异构体 Z 的含量低约十倍）显示出作为 AD 相关靶点乙酰胆碱酯酶双重抑制剂的最佳活性。 AChE) 和单胺氧化酶 B (MAO-B)。在此，我们进一步研究了具有不同体积和亲脂性烷基的非共轭叔氨基部分的可光致异构化的2-亚苄基茚满-1-酮类似物1b-h。对于每种化合物，研究了热稳定的 E 几何异构体以及在光稳态（PSS，75% Z）下通过 UV-B 光照射产生的 E/Z 混合物对人 ChE 和 MAO 的抑制作用。N-苄基（乙基）氨基类似物的纯

  DOI：

  10.3390/molecules28155857

文献信息

• SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES
  申请人：UNIVERSITÉ LAVAL

  公开号：US20160200685A1

  公开（公告）日：2016-07-14

  Provided are compounds of general formula A and A′, wherein X 1 and X 2 are each C, CH or N; R 3 and R 4 are each H, optionally substituted C 1 -C 30 saturated or unsaturated chemical group, or together form an optionally substituted C 5 -C 8 cycle; Z 1 ; Z 2 and Z 3 are each N or CH; V is C═O, C═S or CH 2 ; n is from 1 to 12; W 1 and W 2 are each H, CH 2 , O or S; and R 1 and R 2 are each H, Cr 1 C 6 alkyl, C 1 C 6 aryl, C 1 C 12 alkylaryl, optionally substituted phenyl, C 1 C 6 alkoxy, C 1 C 6 thioalkoxy, F, Cl, Br or I. These compounds inhibit steroid sulfatase (STS), act as selective estrogen receptor modulators (SERMs), increase alkaline phosphatase (ALP) activity, and are useful in the treatment of medical conditions involving hormones such as breast cancer, prostate cancer, endometriosis, osteoporosis, benign prostatic hyperplasia and endometrial cancer.

  提供了一般式为A和A'的化合物，其中X1和X2分别为C、CH或N；R3和R4分别为H、可选取代的C1-C30饱和或不饱和化学基团，或共同形成可选取代的C5-C8环；Z1、Z2和Z3分别为N或CH；V为C═O、C═S或CH2；n为1至12；W1和W2分别为H、 、O或S；R1和R2分别为H、Cr1C6烷基、C1C6芳基、C1C12烷基芳基、可选取代的苯基、C1C6烷氧基、C1C6硫代烷氧基、F、Cl、Br或I。这些化合物抑制类固醇磺酸酯酶（STS），作为选择性雌激素受体调节剂（SERMs），增加碱性磷酸酶（ALP）活性，并可用于治疗涉及激素的医疗条件，如乳腺癌、前列腺癌、子宫内膜异位症、骨质疏松症、良性前列腺增生和子宫内膜癌。
• US9708305B2
  申请人：——

  公开号：US9708305B2

  公开（公告）日：2017-07-18
• [EN] COMPOUNDS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES<br/>[FR] COMPOSÉS DE TRAITEMENT DE MALADIES HORMONODÉPENDANTES
  申请人：UNIV LAVAL

  公开号：WO2015024111A1

  公开（公告）日：2015-02-26

  Provided are compounds of general formula A and A', wherein X1 and X2 are each C, CH or N; R3 and R4 are each H, optionally substituted C1-C30 saturated or unsaturated chemical group, or together form an optionally substituted C5-C8 cycle; Z1; Z2 and Z3 are each N or CH; V is C=0, C=S or CH2; n is from 1 to 12; W1 and W2 are each H, CH2, O or S; and R1 and R2 are each H, Cr1C6 alkyl, C1C6 aryl, C1C12 alkylaryl, optionally substituted phenyl, C1C6 alkoxy, C1C6 thioalkoxy, F, CI, Br or I. These compounds inhibit steroid sulfatase (STS), act as selective estrogen receptor modulators (SERMs), increase alkaline phosphatase (ALP) activity, and are useful in the treatment of medical conditions involving hormones such as breast cancer, prostate cancer, endometriosis, osteoporosis, benign prostatic hyperplasia and endometrial cancer.